StammzelleWays to personalized medicine for gastric cancer;Wege zur personalisierten medizin beim magenkarzinom

Pathologe

Volumn 34, Issue 5, 2013, Pages 403-412

  Rocken C ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Diagnostic target structures; G protein coupled; Receptors; Stem cells; WNT signalling pathway

Indexed keywords

ANTINEOPLASTIC AGENT; G PROTEIN COUPLED RECEPTOR; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER STAGING; DRUG EFFECT; GASTRECTOMY; GENETICS; HUMAN; LYMPH NODE METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PATHOLOGY; PERSONALIZED MEDICINE; PROGNOSIS; STOMACH TUMOR; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; GASTRECTOMY; HUMANS; INDIVIDUALIZED MEDICINE; LYMPHATIC METASTASIS; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; RECEPTORS, G-PROTEIN-COUPLED; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84893685584     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-013-1785-y     Document Type: Article

References (60)

1. Ahn HS, Lee HJ, Hahn S et al (2010) Evaluation of the seventh American Joint Committee on Cancer/International Union against cancer classification of gastric adenocarcinoma in comparison with the sixth classification. Cancer 116:5592-5598
2. Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697
3. Barker N, Clevers H (2010) Leucine-rich repeat-containing G-protein-coupled receptors as markers of adult stem cells. Gastroenterology 138:1681-1696
4. Becker K, Langer R, Reim D et al (2011) Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 253:934-939
5. Becker K, Mueller JD, Schulmacher C et al (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98:1521-1530
6. Becker K, Reim D, Novotny A et al (2012) Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery. Ann Surg 256:1002-1007
7. Carl-McGrath S, Lendeckel U et al (2006) Ectopeptidases in tumour biology: a review. Histol Histopathol 21:1339-1353
8. Carl-McGrath S, Lendeckel U, Ebert M et al (2004) The ectopeptidases CD10, CD13, CD26, and CD143 are upregulated in gastric cancer. Int J Oncol 25:1223-1232
9. Carneiro F (1997) Classification of gastric carcinomas. Curr Diagn Pathol 4:51-59
10. Chua TC, Merrett ND (2012) Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes - a systematic review. Int J Cancer 130:2845-2856
11. Chung S, Funakoshi T, Civelli O (2008) Orphan GPCR research. Br J Pharmacol 153(Suppl 1):S339-S346
12. Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20
13. Gasparo M de, Catt KJ, Inagami T et al (2000) International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52:415-472
14. Deng N, Goh LK, Wang H et al (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61:673-684
15. Domanska UM, Kruizinga RC, Nagengast WB et al (2013) A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer 49:219-230
16. Dorsam RT, Gutkind JS (2007) G-protein-coupled receptors and cancer. Nat Rev Cancer 7:79-94
17. Ebert MP, Lendeckel U, Westphal S et al (2005) The angiotensin I-converting enzyme gene insertion/deletion polymorphism is linked to early gastric cancer. Cancer Epidemiol Biomarkers Prev 14:2987-2989
18. Fang WL, Huang KH, Chen JH et al (2011) Comparison of the survival difference between AJCC 6th and 7th editions for gastric cancer patients. World J Surg 35:2723-2729
19. Fujita T (2013) Targeted therapy for gastric cancer. Lancet Oncol 14:440-442
20. Goseki N, Takizawa T, Koike M (1992) Differences in the mode of the extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma. Gut 33:606-612
21. Houghton J, Stoicov C, Nomura S et al (2004) Gastric cancer originating from bone marrow-derived cells. Science 306:1568-1571
22. Ingold B, Simon E, Ungethum U et al (2010) Vascular CXCR4 expression - a novel antiangiogenic target in gastric cancer? PLoS One 5:e10087
23. Jorgensen JT, Hersom M (2012) HER2 as a prognostic marker in gastric cancer - a systematic analysis of data from the literature. J Cancer 3:137-144
24. Kamposioras K, Pentheroudakis G, Pectasides D et al (2011) Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol 78:112-126
25. Kaschina E, Unger T (2003) Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 12:70-88
26. Kim SH, Ha TK, Kwon SJ (2011) Evaluation of the 7th AJCC TNM staging system in point of lymph node classification. J Gastric Cancer 11:94-100
27. Kim ST, Park KH, Oh SC et al (2012) How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy? Oncology 83:354-360
28. Koizumi K, Kato S, Sakurai H et al (2012) Therapeutics target of CXCR4 and its downstream in peritoneal carcinomatosis of gastric cancer. Front Biosci (Schol Ed) 4:269-276
29. Lauren T (1965) The two histologic main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 64:31-49
30. Lauwers GY, Carneiro F, Graham DY et al (2010) Tumours of the stomach. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (Hrsg) WHO classification of tumours of the digestive system. International Agency for Research on Cancer (IARC), Lyon, S 48-80
31. Lee HE, Kim MA, Lee HS et al (2012) MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 107:325-333
32. Lordick F, Kang YK, Chung HC et al (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14:490-499
33. Marrelli D, Morgagni P, Coniglio A et al (2012) Prognostic value of the 7th AJCC/UICC TNM classification of noncardia gastric cancer: analysis of a large series from specialized Western centers. Ann Surg 255:486-491
34. Ming SC (1977) Gastric carcinoma. A pathobiological classification. Cancer 39:2475-2485
35. Moch H, Blank PR, Dietel M et al (2012) Personalized cancer medicine and the future of pathology. Virchows Arch 460:3-8
36. Moehler M, Al-Batran SE, Andus T et al (2011) German S3-guideline ,diagnosis and treatment of esophagogastric cancer". Z Gastroenterol 49:461-531
37. Mulligan RM (1972) Histogenesis and biologic behavior of gastric carcinoma. Pathol Annu 7:349-415
38. Nakamura K, Sugano H, Takagi K (1968) Carcinoma of the stomach in incipient phase: its histogenesis and histological appearances. Gann 59:251-258
39. Pierce KL, Premont RT, Lefkowitz RJ (2002) Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3:639-650
40. Qiu MZ, Wang ZQ, Zhang DS et al (2011) Comparison of 6th and 7th AJCC TNM staging classification for carcinoma of the stomach in China. Ann Surg Oncol 18:1869-1876
41. Reim D, Loos M, Vogl F et al (2013) Prognostic implications of the seventh edition of the international union against cancer classification for patients with gastric cancer: the Western experience of patients treated in a single-center European institution. J Clin Oncol 31:263-271
42. Riordan JF (2003) Angiotensin-I-converting enzyme and its relatives. Genome Biol 4:225
43. Robert Koch-Institut (Hrsg) Verbreitung von Krebserkrankungen in Deutschland. Entwicklung der Prävalenzen zwischen 1990 und 2010. Beiträge zur Gesundheitsberichterstattung des Bundes. 1990-2010, 37-44. 23-2-2010. Berlin, RKI
44. Röcken C, Lendeckel U, Dierkes J et al (2005) The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism. Clin Cancer Res 11:2526-2530
45. Röcken C, Röhl FW, Diebler E et al (2007) The angiotensin II/angiotensin II-receptor-system correlates with nodal spread in intestinal-type gastric cancer. Cancer Epidemiol Biomarkers Prev 16:1206-1212
46. Rüschoff J, Dietel M, Baretton G et al (2010) HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 457:299-307
47. Scheel C, Weinberg RA (2012) Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin Cancer Biol 22(5-6):396-403
48. Schmiegel W, Reinacher-Schick A, Arnold D et al (2008) Update S3-guideline ,colorectal cancer" 2008. Z Gastroenterol 46:799-840
49. Schmuck R, Warneke V, Behrens HM et al (2011) Genotypic and phenotypic characterization of side population of gastric cancer cell lines. Am J Pathol 178:1792-1804
50. Simon E, Petke D, Boger C et al (2012) The spatial distribution of LGR5+ cells correlates with gastric cancer progression. PLoS One 7:e35486
51. Sobin LH, Gospodarowicz M, Wittekind C (2009) TNM classification of malignant tumours. Wiley-Blackwell, Weinheim
52. Steffen JS, Simon E, Warneke V et al (2012) LGR4 and LGR6 are differentially expressed and of putative tumor biological significance in gastric carcinoma. Virchows Arch 461:355-365
53. Sun Z, Wang ZN, Zhu Z et al (2012) Evaluation of the seventh edition of American Joint Committee on Cancer TNM staging system for gastric cancer: results from a Chinese monoinstitutional study. Ann Surg Oncol 19:1918-1927
54. Suzuki Y, Ruiz-Ortega M, Lorenzo O et al (2003) Inflammation and angiotensin II. Int J Biochem Cell Biol 35:881-900
55. Tan IB, Ivanova T, Lim KH et al (2011) Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 141:476-485, 485.e1-485.e11
56. Varon C, Dubus P, Mazurier F et al (2012) Helicobacter pylori infection recruits bone marrow-derived cells that participate in gastric preneoplasia in mice. Gastroenterology 142:281-291
57. Warneke V, Behrens HM, Haag J et al (2013) Prognostic and putative redictive biomarkers of gastric cancer for personalized medicine. Diagn Mol Pathol. doi: 10.1097/PDM.0b013e318284188e
58. Warneke VS, Behrens HM, Böger C et al (2013) Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann Oncol 24:725-733
59. Warneke VS, Behrens HM, Hartmann JT et al (2011) Cohort study based on the seventh edition of the TNM classification for gastric cancer: proposal of a new staging system. J Clin Oncol 29:2364-2371
60. Zang ZJ, Cutcutache I, Poon SL et al (2012) Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 44:570-574